Author: Chu, Helen Y.; Renaud, Christian; Ficken, Elle; Thomson, Blythe; Kuypers, Jane; Englund, Janet A.
Title: Respiratory Tract Infections Due to Human Metapneumovirus in Immunocompromised Children Document date: 2014_10_21
ID: ujvbm6ae_27
Snippet: A prospective randomized study of ribavirin and IVIG administration, or of newer therapeutic agents under development for treatment of paramyxovirus infections [24, 25] , would be helpful given the high morbidity associated with hMPV in the immunocompromised population. In particular, a study of the use of novel agents, including fusion inhibitors [26] , could be studied in this population given their potential to serve as postexposure prophylaxi.....
Document: A prospective randomized study of ribavirin and IVIG administration, or of newer therapeutic agents under development for treatment of paramyxovirus infections [24, 25] , would be helpful given the high morbidity associated with hMPV in the immunocompromised population. In particular, a study of the use of novel agents, including fusion inhibitors [26] , could be studied in this population given their potential to serve as postexposure prophylaxis in high-risk individuals. The documentation of severe hMPV disease in immunocompromised children supports previous data documenting severe and fatal hMPV disease reported in adult HSCT recipients [9, 13] and highlights the need for treatment options in this population.
Search related documents:
Co phrase search for related documents- adult HSCT recipient and HSCT recipient: 1
- adult HSCT recipient and IVIG administration: 1
- adult HSCT recipient and severe hmpv disease: 1
- fusion inhibitor and novel agent: 1
- high morbidity and IVIG administration: 1
- high morbidity and novel agent: 1, 2, 3, 4, 5, 6, 7, 8, 9
- high morbidity and population study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- high morbidity and randomized study: 1, 2, 3, 4, 5, 6
- high morbidity and therapeutic agent: 1, 2, 3, 4, 5
- high morbidity and treatment option: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- high risk and hmpv disease: 1, 2
- high risk and HSCT recipient: 1, 2, 3
- high risk and IVIG administration: 1, 2, 3
- high risk and novel agent: 1, 2, 3, 4, 5, 6, 7
- high risk and population study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- high risk and postexposure prophylaxis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- high risk and randomized study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- high risk and severe hmpv disease: 1
- high risk and therapeutic agent: 1, 2
Co phrase search for related documents, hyperlinks ordered by date